PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F18%3AN0000097" target="_blank" >RIV/00064173:_____/18:N0000097 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/17:43915709

Result on the web

<a href="http://dx.doi.org/10.1016/S0140-6736(17)32134-7" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(17)32134-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S0140-6736(17)32134-7" target="_blank" >10.1016/S0140-6736(17)32134-7</a>

Result language

angličtina

Original language name

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Original language description

The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense of severe toxicities. Individual patients might be cured with less burdensome therapy. We investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it for PET-2-negative patients. METHODS: In this open-label, randomised, parallel-group phase 3 trial, we recruited patients aged 18-60 years with newly diagnosed, advanced-stage Hodgkin's lymphoma in 301 hospitals and private practices in Germany, Switzerland, Austria, the Netherlands, and the Czech Republic. After central review of PET-2, patients were assigned (1:1) to one of two parallel treatment groups on the basis of their PET-2 result. Patients with positive PET-2 were randomised to receive six additional cycles of either standard eBEACOPP (8 x eBEACOPP in total) or eBEACOPP with rituximab (8 x R-eBEACOPP). Those with negative PET-2 were randomised between standard treatment with six additional cycles of eBEACOPP (8 x eBEACOPP) or experimental treatment with two additional cycles (4 x eBEACOPP). A protocol amendment in June, 2011, introduced a reduction of standard therapy to 6 x eBEACOPP; after this point, patients with positive PET-2 were no longer randomised and were all assigned to receive 6 x eBEACOPP and patients with negative PET-2 were randomly assigned to 6 x eBEACOPP (standard) or 4 x eBEACOPP (experimental).

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The Lancet

ISSN

0140-6736

e-ISSN

1474-547X

Volume of the periodical

390

Issue of the periodical within the volume

10114

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

2790-2802

UT code for WoS article

000418669800024

EID of the result in the Scopus database

2-s2.0-85040703989